Ernst, Moritz and Duehrsen, Ulrich and Hellwig, Dirk and Lenz, Georg and Skoetz, Nicole and Borchmann, Peter (2023) Diffuse Large B-Cell Lymphoma and Related Entities. DEUTSCHES ARZTEBLATT INTERNATIONAL, 120 (17). 289-+. ISSN 1866-0452,
Full text not available from this repository. (Request a copy)Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common malignant B-cell neoplasm, with an incidence of 5.6 per 100 000 persons per year and a mean age of onset of approximately 65 years. It is an aggressive type of non-Hodgkin's lymphoma requiring urgent treatment with curative intent. Evidence-based guidelines have not been available to date.Methods: For this first international evidence-based DLBCL-specific guideline, various systematic literature searches were performed. 5 systematic reviews, 21 randomized controlled trials (RCTs), and 36 non-randomized studies were used to formulate 42 recommendations. 142 were formulated on the basis of expert consensus. All recommendations were approved in a structured consensus-finding process.Results: For staging, combined positron emission tomography and computed tomography (PET/CT) should be performed (evidence: a prospective registry study). For all patients with a new diagnosis of DLBCL and without contraindications, R-CHOP based immunochemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) should be initiated with curative intent (evidence: RCTs). The individual treatment strategy is tailored to the patient's age and risk constellation. Once immunochemotherapy has been completed, PET/CT should be performed again to check for remission. Patients with PET-positive residual disease that is amenable to radiotherapy should be treated with consolidating irradiation (evidence: retrospective cohort study).Conclusion: This clinical practice guideline on the diagnosis, treatment, and followup of patients with DLBCL and related entities provides a standardized clinical management approach, identifies areas where improvement would be desirable, and can serve as a basis for the development of further studies.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | RANDOMIZED CONTROLLED-TRIAL; NON-HODGKIN-LYMPHOMA; HIGH-RISK PATIENTS; PLUS BENDAMUSTINE; CHOP CHEMOTHERAPY; RITUXIMAB-CHOP; OPEN-LABEL; PHASE-II; YOUNG; TRANSPLANTATION; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Nuklearmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 Mar 2024 14:58 |
| Last Modified: | 19 Mar 2024 14:58 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60370 |
Actions (login required)
 |
View Item |
